Xenotransplantation (xenos- from the Greek meaning "foreign"), is the transplantation of living cells, tissues or organs from one species to another. Such cells, tissues or organs are called xenografts or xenotransplants. In contrast, the term allotransplantation refers to a same-species transplant. Human xenotransplantation offers a potential treatment for end-stage organ failure, a significant health problem in parts of the industrialized world. It also raises many novel medical, legal and ethical issues. A continuing concern is that many animals, such as pigs, have a shorter lifespan than humans, meaning that their tissues age at a quicker rate. Disease transmission (xenozoonosis) and permanent alteration to the genetic code of animals are also causes for concern. A few successful cases of xenotransplantation are published.
It is not uncommon for patients and physicians to use the term "allograft" imprecisely to refer to either allograft (human-to-human) or xenograft (animal-to-human), but it is helpful scientifically (for those searching or reading the scientific literature) to maintain the more precise distinction in usage.
- 1 History
- 2 Potential future uses
- 3 Potential future animal organ donors
- 4 Barriers and issues
- 4.1 Immunologic barriers
- 4.2 Physiology
- 4.3 Xenozoonosis
- 4.4 Ethics
- 5 See also
- 6 References
- 7 External links
|This section requires expansion. (October 2012)|
An American infant girl known as "Baby Fae" with hypoplastic left heart syndrome was the first infant recipient of a xenotransplantation, when she received a baboon heart in 1984. The procedure was performed by Leonard L. Bailey at Loma Linda University Medical Center in Loma Linda, California. Fae died 21 days later due to a humoral-based graft rejection thought to be caused mainly by an ABO blood type mismatch, considered unavoidable due to the rarity of type O baboons. The graft was meant to be temporary, but unfortunately a suitable allograft replacement could not be found in time.
Xenotransplantation of human tumor cells into immunocompromised mice is a research technique frequently used in oncology research. It is used to predict the sensitivity of the transplanted tumor to various cancer treatments; several companies offer this service, including the Jackson Laboratory and Altogen Labs.
Potential future uses
A worldwide shortage of organs for clinical implantation causes about 20–35% of patients who need replacement organs to die on the waiting list. Certain procedures, some of which are being investigated in early clinical trials, aim to use cells or tissues from other species to treat life-threatening and debilitating illnesses such as cancer, diabetes, liver failure and Parkinson's disease. If vitrification can be perfected, it could allow for long-term storage of xenogenic cells, tissues and organs so that they would be more readily available for transplant.
Xenotransplants could save thousands of patients waiting for donated organs. The animal organ, probably from a pig or baboon could be genetically altered with human genes to trick a patient’s immune system into accepting it as a part of its own body. They have re-emerged because of the lack of organs available and the constant battle to keep immune systems from rejecting allotransplants. Xenotransplants are thus potentially a more effective alternative.
Potential future animal organ donors
Since they are the closest relatives to humans, nonhuman primates were first considered as a potential organ source for xenotransplantation to humans. Chimpanzees were originally considered the best option since their organs are of similar size, and they have good blood type compatibility with humans, which makes them potential candidates for xenotransfusions. However, since chimpanzees are listed as an endangered species, other potential donors were sought. Baboons are more readily available, but impractical as potential donors. Problems include their smaller body size, the infrequency of blood group O (the universal donor), their long gestation period, and their typically small number of offspring. In addition, a major problem with the use of nonhuman primates is the increased risk of disease transmission, since they are so closely related to humans.
Pigs are currently thought to be the best candidates for organ donation. The risk of cross-species disease transmission is decreased because of their increased phylogenetic distance from humans. They are readily available, their organs are anatomically comparable in size, and new infectious agents are less likely since they have been in close contact with humans through domestication for many generations. Current experiments in xenotransplantation most often use pigs as the donor, and baboons as human models.
In the field of regenerative medicine pancreatogenesis- or nephrogenesis-disabled pig embryos, unable to form a specific organ, allows experimentation toward the in vivo generation of functional organs from xenogenic pluripotent stem cells in large animals via compensation for an empty developmental niche (blastocyst complementation). Such experiments provide the basis for potential future application of blastocyst complementation to generate transplantable human organs from the patient's own cells, using livestock animals, to increase quality of life for those with end-stage organ failure.
Barriers and issues
To date no xenotransplantation trials have been entirely successful due to the many obstacles arising from the response of the recipient’s immune system. This response, which is generally more extreme than in allotransplantations, ultimately results in rejection of the xenograft, and can in some cases result in the immediate death of the recipient. There are several types of rejection organ xenografts are faced with, these include:
- Hyperacute rejection
- Acute vascular rejection
- Cellular rejection
- Chronic rejection
This rapid and violent type of rejection occurs within minutes to hours from the time of the transplant. It is mediated by the binding of XNAs (xenoreactive natural antibodies) to the donor endothelium, causing activation of the human complement system, which results in endothelial damage, inflammation, thrombosis and necrosis of the transplant. XNAs are first produced and begin circulating in the blood in neonates, after colonization of the bowel by bacteria with galactose moieties on their cell walls. Most of these antibodies are the IgM class, but also include IgG, and IgA.
The epitope XNAs target is an α-linked galactose moiety, Gal-α-1,3Gal (also called the α-Gal epitope), produced by the enzyme α-galactosyl transferase. Most non-primates contain this enzyme thus, this epitope is present on the organ epithelium and is perceived as a foreign antigen by primates, which lack the galactosyl transferase enzyme. In pig to primate xenotransplantation, XNAs recognize porcine glycoproteins of the integrin family.
The binding of XNAs initiate complement activation through the classical complement pathway. Complement activation causes a cascade of events leading to: destruction of endothelial cells, platelet degranulation, inflammation, coagulation, fibrin deposition, and hemorrhage. The end result is thrombosis and necrosis of the xenograft.
Overcoming hyperacute rejection
Since hyperacute rejection presents such a barrier to the success of xenografts several strategies to overcome it are under investigation:
Interruption of the complement cascade
- The recipient's complement cascade can be inhibited through the use of cobra venom factor (which depletes C3), soluble complement receptor type 1, anti-C5 antibodies, or C1 inhibitor (C1-INH). Disadvantages of this approach include the toxicity of cobra venom factor, and most importantly these treatments would deprive the individual of a functional complement system.
Transgenic organs (Genetically engineered pigs)
- 1,3 galactosyl transferase gene knockouts – These pigs don’t contain the gene that codes for the enzyme responsible for expression of the immunogeneic gal-α-1,3Gal moiety (the α-Gal epitope).
- Increased expression of H-transferase (α 1,2 fucosyltransferase), an enzyme that competes with galactosyl transferase. Experiments have shown this reduces α-Gal expression by 70%.
- Expression of human complement regulators (CD55, CD46, and CD59) to inhibit the complement cascade.
- Plasmaphoresis, on humans to remove 1,3 galactosyltransferase, reduces the risk of activation of effector cells such as CTL (CD8 T cells), complement pathway activation and delayed type hypersensitivity (DTH).
Acute vascular rejection
Also known as delayed xenoactive rejection, this type of rejection occurs in discordant xenografts within 2 to 3 days, if hyperacute rejection is prevented. The process is much more complex than hyperacute rejection and is currently not completely understood. Acute vascular rejection requires de novo protein synthesis and is driven by interactions between the graft endothelial cells and host antibodies, macrophages, and platelets. The response is characterized by an inflammatory infiltrate of mostly macrophages and natural killer cells (with small numbers of T cells), intravascular thrombosis, and fibrinoid necrosis of vessel walls.
Binding of the previously mentioned XNAs to the donor endothelium leads to the activation of host macrophages as well as the endothelium itself. The endothelium activation is considered type II since gene induction and protein synthesis are involved. The binding of XNAs ultimately leads to the development of a procoagulant state, the secretion of inflammatory cytokines and chemokines, as well as expression of leukocyte adhesion molecules such as E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1).
This response is further perpetuated as normally binding between regulatory proteins and their ligands aid in the control of coagulation and inflammatory responses. However, due to molecular incompatibilities between the molecules of the donor species and recipient (such as porcine major histocompatibility complex molecules and human natural killer cells), this may not occur.
Overcoming acute vascular rejection
Due to its complexity, the use of immunosuppressive drugs along with a wide array of approaches are necessary to prevent acute vascular rejection, and include:
- Administering a synthetic thrombin inhibitor to modulate thrombogenesis
- Depletion of anti-galactose antibodies (XNAs) by techniques such as immunoadsorption, to prevent endothelial cell activation
- Inhibiting activation of macrophages (stimulated by CD4+ T cells) and NK cells (stimulated by the release of Il-2). Thus, the role of MHC molecules and T cell responses in activation would have to be reassessed for each species combo.
If hyperacute and acute vascular rejection are avoided accommodation is possible, which is the survival of the xenograft despite the presence of circulating XNAs. The graft is given a break from humoral rejection when the complement cascade is interrupted, circulating antibodies are removed, or their function is changed, or there is a change in the expression of surface antigens on the graft. This allows the xenograft to up-regulate and express protective genes, which aid in resistance to injury, such as heme oxygenase-1 (an enzyme that catalyzes the degradation of heme).
Rejection of the xenograft in hyperactute and acute vascular rejection is due to the response of the humoral immune system, since the response is elicited by the XNAs. Cellular rejection is based on cellular immunity, and is mediated by:
- Natural killer cells, which accumulate in and damage the xenograft; and
- T-lymphocytes – which are activated by MHC molecules through both direct and indirect xenorecognition.
In direct xenorecognition, antigen presenting cells from the xenograft present peptides to recipient CD4+ T cells via xenogeneic MHC class II molecules, resulting in the production of interleukin 2 (IL-2). Indirect xenorecognition involves the presentation of antigens from the xenograft by recipient antigen presenting cells to CD4+ T cells. Antigens of phagocytosed graft cells can also be presented by the host’s class I MHC molecules to CD8+ T cells.
The strength of cellular rejection in xenografts remains uncertain, however it is expected to be stronger than in allografts due to differences in peptides among different animals. This leads to more antigens potentially recognized as foreign, thus eliciting a greater indirect xenogenic response.
Overcoming cellular rejection
A proposed strategy to avoid cellular rejection is to induce donor non-responsiveness using hematopoietic chimerism. Donor stem cells are introduced into the bone marrow of the recipient, where they coexist with the recipient’s stem cells. The bone marrow stem cells give rise to cells of all hematopoietic lineages, through the process of hematopoiesis. Lymphoid progenitor cells are created by this process and move to the thymus where negative selection eliminates T cells found to be reactive to self. The existence of donor stem cells in the recipient’s bone marrow causes donor reactive T cells to be considered self and undergo apoptosis.
Chronic rejection is slow and progressive, and usually occurs in transplants that survive the initial rejection phases. Scientists are still unclear how chronic rejection exactly works, research in this area is difficult since xenografts rarely survive past the initial acute rejection phases. Nonetheless, it is known is that XNAs and the complement system are not primarily involved. Fibrosis in the xenograft occurs as a result of immune reactions, cytokines (which stimulate fibroblasts), or healing (following cellular necrosis in acute rejection). Perhaps the major cause of chronic rejection is arteriosclerosis. Lymphocytes, which were previously activated by antigens in the vessel wall of the graft, activate macrophages to secrete smooth muscle growth factors. This results in a build up of smooth muscle cells on the vessel walls, causing the hardening and narrowing of vessels within the graft. Chronic rejection leads to pathologic changes of the organ, and is why transplants must be replaced after so many years. It is also anticipated that chronic rejection will be more aggressive in xenotransplants as opposed to allotransplants.
Successful efforts have been made to create knockout mice without α1,3GT; the resulting reduction in the highly immunogenic αGal epitope has resulted in the reduction of the occurrence of hyperacute rejection, but has not eliminated other barriers to xenotransplantation such as dysregulated coagulation, also known as coagulopathy.
Different organ xenotransplants result in different responses in clotting. For example, kidney transplants result in a higher degree of coagulopathy, or impaired clotting, than cardiac transplants, whereas liver xenografts result in severe thrombocytopenia, causing recipient death within a few days due to bleeding. An alternate clotting disorder, thrombosis, may be initiated by preexisting antibodies that affect the protein C anticoagulant system. Due to this effect, porcine donors must be extensively screened before transplantation. Studies have also shown that some porcine transplant cells are able to induce human tissue factor expression, thus stimulating platelet and monocyte aggregation around the xenotransplanted organ, causing severe clotting. Additionally, spontaneous platelet accumulation may be caused by contact with pig von Willebrand factor.
Just as the α1,3G epitope is a major problem in xenotransplantation, so too is dysregulated coagulation a cause of concern. Transgenic pigs that can control for variable coagulant activity based on the specific organ transplanted would make xenotransplantation a more readily available solution for the 70,000 patients per year who do not receive a human donation of the organ or tissue they need.
Extensive research is required to determine whether animal organs can replace the physiological functions of human organs. Many issues include:
- Size – Differences in organ size limit the range of potential recipients of xenotransplants.
- Longevity – The lifespan of most pigs is roughly 15 years, currently it is unknown whether or not a xenograft may be able to last longer than that.
- Hormone and protein differences – Some proteins will be molecularly incompatible, which could cause malfunction of important regulatory processes. These differences also make the prospect of hepatic xenotransplantation less promising, since the liver plays an important role in the production of so many proteins.
- Environment – For example, pig hearts work in a different anatomical site and under different hydrostatic pressure than in humans.
- Temperature – The body temperature of pigs is 39 °C (2 °C above the average human body temperature). Implications of this difference, if any, on the activity of important enzymes are currently unknown.
Xenozoonosis, also known as zoonosis or xenosis, is the transmission of infectious agents between species via xenograft. Animal to human infection is normally rare, but has occurred in the past. An example of such is the avian influenza, when an influenza A virus was passed from birds to humans. Xenotransplantation may increase the chance of disease transmission for 3 reasons:
- Implantation breaches the physical barrier that normally helps to prevent disease transmission,
- The recipient of the transplant will be severely immunosuppressed; and
- Human complement regulators (CD46, CD55, and CD59) expressed in transgenic pigs have been shown to serve as virus receptors, and may also help to protect viruses from attack by the complement system.
Examples of viruses carried by pigs include porcine herpesvirus, rotavirus, parvovirus, and circovirus. Porcine herpesviruses and rotaviruses can be eliminated from the donor pool by screening, however others (such as parvovirus and circovirus) may contaminate food and footwear then re-infect the herd. Thus, pigs to be used as organ donors must be housed under strict regulations and screened regularly for microbes and pathogens. Unknown viruses, as well as those not harmful in the animal, may also pose risks (Takeuchi and George, 2000). Of particular concern are PERVS (porcine endogenous retroviruses), vertically transmitted microbes that embed in swine genomes. The risks with xenosis are twofold, as not only could the individual become infected, but a novel infection could initiate an epidemic in the human population. Because of this risk, the FDA has suggested any recipients of xenotransplants shall be closely monitored for the remainder of their life, and quarantined if they show signs of xenosis.
Baboons and pigs carry myriad transmittable agents that are harmless in their natural host, but extremely toxic and deadly in humans. HIV is an example of a disease believed to have jumped from monkeys to humans. Researchers also do not know if an outbreak of infectious diseases could occur and if they could contain the outbreak even though they have measures for control. Another obstacle facing xenotransplants is that of the body’s rejection of foreign objects by its immune system. These antigens (foreign objects) are often treated with powerful immunosuppressive drugs that could, in turn, make the patient vulnerable to other infections and actually aid the disease. This is the reason the organs would have to be altered to fit the patients' DNA (histocompatibility).
In 2005, the Australian National Health and Medical Research Council (NHMRC) declared an eighteen-year moratorium on all animal-to-human transplantation, concluding that the risks of transmission of animal viruses to patients and the wider community had not been resolved. This was repealed in 2009 after an NHMRC review stated "... the risks, if appropriately regulated, are minimal and acceptable given the potential benefits.", citing international developments on the management and regulation of xenotransplantation by the World Health Organisation and the European Medicines Agency.
Porcine endogenous retroviruses
Endogenous retroviruses are remnants of ancient viral infections, found in the genomes of most, if not all, mammalian species. Integrated into the chromosomal DNA, they are vertically transferred through inheritance. Due to the many deletions and mutations they accumulate over time, they usually are not infectious in the host species, however the virus may become infectious in another species. PERVS were originally discovered as retrovirus particles released from cultured porcine kidney cells. Most breeds of swine harbor approximately 50 PERV genomes in their DNA. Although it is likely that most of these are defective, some may be able to produce infectious viruses so every proviral genome must be sequenced to identify which ones pose a threat. In addition, through complementation and genetic recombination, two defective PERV genomes could give rise to an infectious virus. There are three subgroups of infectious PERVs (PERV-A, PERV-B, and PERV-C). Experiments have shown that PERV-A and PERV-B can infect human cells in culture. To date no experimental xenotransplantations have demonstrated PERV transmission, yet this does not mean PERV infections in humans are impossible.
Xenografts have been a controversial procedure since they were first attempted. Many, including animal rights groups, strongly oppose killing animals to harvest their organs for human use. The prohibition of the consumption of pig does pose problems in Jewish and Islamic communities. In general, the use of pig and cow tissue in humans has been met with little resistance, save some religious beliefs and a few philosophical objections. Experimentation without consent doctrines are now followed, which was not the case in the past, which may lead to new religious guidelines to further medical research on pronounced ecumenical guidelines. The "Common Rule" is the United States bio-ethics mandate as of 2011.
Informed consent of patient
Autonomy and Informed consent are important when considering the future uses of xenotransplantation. A patient undergoing xenotransplantation should be fully aware of the procedure and should have no outside force influencing their choice. The patient should understand the risks and benefits of such a transplantation. However, it has been suggested that friends and family members should also give consent. The reason for this being is that the repercussions of transplantation are high, with the potential of diseases and viruses crossing over to humans from the transplantation. Close contacts are at risk for such infections. Monitoring of close relations may also be required to insure that xenozoonosis is not occurring. The question then becomes does the autonomy of the patient become limited based on the willingness or unwillingness of friends and family to give consent, and are the principles of confidentiality broken?
The safety of public health is a factor to be considered. If there is any risk to the public at all for an outbreak from transplantation there must be procedures in place to protect the public. Not only does the recipient of the transplantation have to understand the risks and benefits, but society must also understand and consent to such an agreement.
The Ethics Committee of the International Xenotransplantation Association points out one major ethical issue is the societal response to such a procedure. The assumption that the recipient of the transplantation will be asked to undergo lifelong monitoring. Lifelong monitoring would deny the recipient the ability to terminate the monitoring at any time, which is in direct opposition of the Declaration of Helsinki and the US Code of Federal Regulations.
Xenotransplantion guidelines in the USA
The Food and Drug Administration (FDA) has also stated that if a transplantation takes place the recipient must undergo monitoring for the rest of that recipient's life time and waive their right to withdraw. The reason for requiring lifelong monitoring is due to the risk of acute infections that may occur. The FDA suggests that a passive screening program should be implemented and should extend for the life of the recipient.
- See also Definition of the World Health Organization
- Kress, J. M. (1998). "Xenotransplantation: Ethics and economics". Food and drug law journal 53 (2): 353–384. PMID 10346691.
- "Organ Transplants from Animals: Examining the Possibilities". Fda.gov. Internet Archive. Archived from the original on 2007-12-10. Retrieved 2009-08-03.
- Bailey, L. L.; Nehlsen-Cannarella, S. L.; Concepcion, W.; Jolley, W. B. (1985). "Baboon-to-human cardiac xenotransplantation in a neonate". JAMA: the Journal of the American Medical Association 254 (23): 3321–3329. doi:10.1001/jama.1985.03360230053022. PMID 2933538.
- Healy, D. G.; Lawler, Z.; McEvoy, O.; Parlon, B.; Baktiari, N.; Egan, J. J.; Hurley, J.; McCarthy, J. F.; Mahon, N.; Wood, A. E. (2005). "Heart transplant candidates: Factors influencing waiting list mortality". Irish medical journal 98 (10): 235–237. PMID 16445141.
- Platt JL, Cascalho M. New and old technologies for organ replacement. Curr Opin Organ Transplant. 2013 Apr;18(2):179-85. PMID 23449347
- van der Windt DJ et al. Clinical islet xenotransplantation: how close are we? Diabetes. 2012 Dec;61(12):3046-55. PMCID PMC3501885 PMID 23172951
- Tisato V, Cozzi E. Xenotransplantation: an overview of the field. Methods Mol Biol. 2012;885:1-16. PMID 22565986
- Bols PE et al. Xenotransplantation in immunodeficient mice to study ovarian follicular development in domestic animals. Theriogenology. 2010 Apr 1;73(6):740-7. PMID 19913288
- Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG, (2012) Patient-derived tumour xenografts as models for oncology drug development. Nature Reviews Clinical Oncology 9:338–350. article doi:10.1038/nrclinonc.2012.61
- Michler, R. (1996). "Xenotransplantation: Risks, Clinical Potential, and Future Prospects". Emerging Infectious Diseases 2 (1): 64–70. doi:10.3201/eid0201.960111. PMC 2639801. PMID 8903201.
- Dooldeniya, M. D.; Warrens, A. N. (2003). "Xenotransplantation: Where are we today?". JRSM 96 (3): 111–117. doi:10.1258/jrsm.96.3.111. PMC 539416.
- Taylor, L. (2007) Xenotransplantation. Emedicine.com
- Hitomi Matsunari, Hiroshi Nagashima, Masahito Watanabe, et al. and Hiromitsu Nakauchi (2013). Blastocyst complementation generates exogenic pancreas in vivo in apancreatic cloned pigs. PNAS, 110(12), 4557–4562, doi:10.1073/pnas.1222902110
- Candinas, D.; Adams, D. H. (2000). "Xenotransplantation: Postponed by a millennium?". QJM 93 (2): 63–66. doi:10.1093/qjmed/93.2.63. PMID 10700475.
- Latemple, D. C.; Galili, U. (1998). "Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase". Xenotransplantation 5 (3): 191–196. doi:10.1111/j.1399-3089.1998.tb00027.x. PMID 9741457.
- Sharma, A.; Okabe, J.; Birch, P.; McClellan, S. B.; Martin, M. J.; Platt, J. L.; Logan, J. S. (1996). "Reduction in the level of Gal(alpha1,3)Gal in transgenic mice and pigs by the expression of an alpha(1,2)fucosyltransferase". Proceedings of the National Academy of Sciences of the United States of America 93 (14): 7190–7195. doi:10.1073/pnas.93.14.7190. PMC 38958. PMID 8692967.
- Huang, J.; Gou, D.; Zhen, C.; Jiang, D.; Mao, X.; Li, W.; Chen, S.; Cai, C. (2001). "Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP". FEMS immunology and medical microbiology 31 (3): 203–209. doi:10.1111/j.1574-695X.2001.tb00521.x. PMID 11720816.
- Takahashi, T.; Saadi, S.; Platt, J. L. (1997). "Recent advances in the immunology of xenotransplantation". Immunologic Research 16 (3): 273–297. doi:10.1007/BF02786395. PMID 9379077.
- Abbas, A., Lichtman, A. (2005) Cellular and Molecular Immunology, 5th ed., pp. 81, 330–333, 381, 386. Elsevier Saunders, Pennsylvania,ISBN 0-7216-0008-5, doi:10.1002/bmb.2004.494032019997.
- Vanderpool, H. Y. (1999). "Xenotransplantation: Progress and promise". BMJ 319 (7220): 1311. doi:10.1136/bmj.319.7220.1311. PMC 1129087. PMID 10559062.
- Cowan PJ, Robson SC, d’Apice AJF. "Controlling coagulation dysregulation in xenotransplantation." Current Opinion in Organ Transplantation (2011). 16: 214-221.
- Ekser B and Cooper DK. "Overcoming the barriers to xenotransplantation: prospects for the future." Expert Rev Clin Immunol (2010). 6(2): 219-230.
- Beigel, J.; Farrar, J.; Han, A.; Hayden, F.; Hyer, R.; De Jong, M.; Lochindarat, S.; Nguyen, T.; Nguyen, T.; Tran, T. H.; Nicoll, A.; Touch, S.; Yuen, K. Y.; Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5 (2005). "Avian Influenza A (H5N1) Infection in Humans". New England Journal of Medicine 353 (13): 1374–1385. doi:10.1056/NEJMra052211. PMID 16192482.
- Takeuchi, Y.; Weiss, R. A. (2000). "Xenotransplantation: Reappraising the risk of retroviral zoonosis". Current opinion in immunology 12 (5): 504–507. doi:10.1016/S0952-7915(00)00128-X. PMID 11007351.
- FDA. (2006) Xenotransplantation Action Plan: FDA Approach to the Regulation of Xenotransplantation. Center for Biologics Evaluation and Research.
- "The Australian National Health and Medical Research Council's 2005 statement on xenotransplantation" (PDF). Archived from the original on 2008-07-22. Retrieved 2008-11-06.
- Dean, Tim (10 December 2009) Xenotransplantation ban lifted in Australia. lifescientist.com.au
- Armstrong, J. A.; Porterfield, J. S.; De Madrid, A. T. (1971). "C-type virus particles in pig kidney cell lines". The Journal of general virology 10 (2): 195–198. doi:10.1099/0022-1317-10-2-195. PMID 4324256.
- Patience, C.; Takeuchi, Y.; Weiss, R. A. (1997). "Infection of human cells by an endogenous retrovirus of pigs". Nature medicine 3 (3): 282–286. doi:10.1038/nm0397-282. PMID 9055854.
- Rogel-Gaillard, C.; Bourgeaux, N.; Billault, A.; Vaiman, M.; Chardon, P. (1999). "Construction of a swine BAC library: Application to the characterization and mapping of porcine type C endoviral elements". Cytogenetics and cell genetics 85 (3–4): 205–211. doi:10.1159/000015294. PMID 10449899.
- Takeuchi, Y.; Patience, C.; Magre, S.; Weiss, R. A.; Banerjee, P. T.; Le Tissier, P.; Stoye, J. P. (1998). "Host range and interference studies of three classes of pig endogenous retrovirus". Journal of virology 72 (12): 9986–9991. PMC 110514. PMID 9811736.
- PETA Media Center: Factsheet: Xenotransplantation. Peta.org. Retrieved on 2013-10-17.
- von Derdidas, Ihrwir (2009) A More Modest Proposal. Hotel St. George Press.
- Ellison T. 2006. Xenotransplantation – ethics and regulation. Xenotransplantation 13:505–509.
- Kaiser M. 2004. Xenotransplantation – Ethical Considerations based on Human and Societal Perspectives. Acta Vet Scand 45:1–9.
- Sykes M, D’Apice A, Sandrin M. 2003. Position Paper of the Ethics Committee of the International Xenotransplantation Association. Xenotransplantation 10:194–203.
- United States Food and Drug Administration. Guidance for Industry: Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of XTx Products in Humans. Washington, DC: US FDA, 2001
|Look up xenotransplantation in Wiktionary, the free dictionary.|
- Xenotransplantation, The official Journal of the International Xenotransplantation Association
- PBS Special on Pig to Human Transplants
- Uncaged Campaigns
- Diaries of Despair
- Campaign for Responsible Transplantation
- The Australian National Health and Medical Research Council's 2005 statement on xenotransplantation
- science.education.nih.gov Snapshots of Science and Medicine: Xenotransplantation